Incidence of HF Therapy Escalation and Time-to-Clinical Worsening in Atrial Shunt- vs. Sham-Treated Patients with HFpEF/HFmrEF During 5-Year Follow-Up: REDUCE LAP-HF II Trial

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker's Bureau - Boston Scientific Corporation; Edwards Lifesciences; Abbott; Medtronic</li></ul>